Phuturdex › Diseases › Liver disease
Drugs in development · updated 30 October 2026
Liver disease: drugs in development
As of 30 October 2026 there are 28 active clinical trials (recruiting or ongoing, phases I–III) on 33 drugs for liver disease. 16 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ElebsiranVIR-2218 | III | 2 | NCT07128550 |
| Pegozafermin | III | 2 | NCT06419374 |
| TobevibartVIR-3434 | III | 2 | NCT07128550 |
| ECUR-506 | III | 1 | NCT06255782 |
| IVA337 | III | 1 | NCT04849728 |
| AHB-137 | II | 2 | NCT07654283 |
| Coenzyme Q10CoQ10 | II | 1 | NCT05984745 |
| ECC0509 | II | 1 | NCT07288138 |
| ECC4703 | II | 1 | NCT07288138 |
| LYG-LIV0001 | II | 1 | NCT04496479 |
| QEL-001 | I–II | 1 | NCT05234190 |
| RTX001 | I–II | 1 | NCT06823713 |
| TAK-242 | II | 1 | NCT06890039 |
| AIR-001 | I | 1 | NCT07431112 |
| INCB123667 | I | 1 | NCT07559474 |
| INCB161734 | I | 1 | NCT07853040 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BulevirtideHepcludex® | III | 2 | NCT07128550 |
| CyclosporineCyclosporine A, Cyclosporin Capsules | III | 1 | NCT07739914 |
| EverolimusRAD001, Everoliumus | III | 1 | NCT07739914 |
| TacrolimusEnvarsus XR, Prograf® | III | 1 | NCT07739914 |
| AtezolizumabTecentriq, MPDL3280A | II | 2 | NCT06096779 |
| Bevacizumabavastin, MVASI | II | 2 | NCT06096779 |
| AtorvastatinLipitor, Atorvaliq® | II | 1 | NCT05028829 |
| DiphenhydramineBenadryl, Benadryl Preservative Free® | II | 1 | NCT04862221 |
| EnoxaparinLovenox, Lovenox (Preservative Free)® | II | 1 | NCT05895136 |
| MethylprednisoloneMethylprednisolon, Methylprenisolone | II | 1 | NCT04862221 |
| PrednisolonePrednisolon, Prenisolone | II | 1 | NCT04862221 |
| ResmetiromMGL-3196, Rezdiffra® | II | 1 | NCT07763015 |
| VimseltinibDCC-3014, Romvimza® | II | 1 | NCT06619561 |
| ApixabanEliquis, Abanta® | I | 1 | NCT04874428 |
| BepirovirsenHibsago® | I | 1 | NCT07905157 |
Sorted by most advanced phase and number of active trials. Showing 15 of 17 drugs.
All 33 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Hepatocellular carcinoma 266 drugs
- Liver neoplasm 86 drugs
- Non-alcoholic Fatty Liver Disease 68 drugs
- Chronic hepatitis B 42 drugs
- Non-small-cell lung carcinoma 726 drugs
- Colorectal neoplasm 534 drugs
- Melanoma 352 drugs
- Ovarian neoplasm 411 drugs
- Stomach neoplasm 340 drugs
- Liver cirrhosis 38 drugs
- Liver Cirrhosis, Biliary 13 drugs
- Renal cell carcinoma 228 drugs
Broader categories
- Digestive System Diseases 36 drugs
- Hepatic insufficiency 11 drugs
- Nutritional and metabolic diseases 5 drugs
- Liver failure 10 drugs
- Infection 71 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D008107 “Liver Diseases”.